Decreased awareness of current smoking among health care providers of HIV-positive compared to HIV-negative veterans

Crothers, Kristina; Goulet, Joseph L.; Rodriguez-Barradas, Maria C.; Gilbert, Cynthia L.; Butt, Adeel A.; Braithwaite, R. Scott; Peck, Robin; Justice, Amy C.; Gibert, Cynthia L
June 2007
JGIM: Journal of General Internal Medicine;Jun2007, Vol. 22 Issue 6, p749
Academic Journal
journal article
Background: Cigarette smoking is an important risk factor for morbidity and mortality in HIV-positive patients on combination antiretroviral therapy.Objective: To determine whether awareness of smoking differs between HIV and non-HIV providers, and to identify factors associated with failure to recognize current smoking.Design: Observational study.Participants: 801 HIV-positive and 602 HIV-negative patients, 72 HIV and 71 non-HIV providers enrolled in the Veterans Aging Cohort 5 Site Study.Measurements: Data sources included patient and provider questionnaires; electronic medical records; and the national administrative VA database. We calculated sensitivity, specificity, and measures of agreement between patient- and provider-reported smoking, and examined factors associated with failure to recognize current smoking using logistic regression.Results: Whereas most providers were correct when they identified a patient as a current smoker (specificity > or = 90%), HIV providers missed current smoking more often (sensitivity 65% for HIV vs. 82% for non-HIV). Kappa scores for current smoking were significantly lower for HIV compared to non-HIV providers (0.55 vs. 0.75, p < .001). In models adjusted for age, gender, race, and other differences, patient HIV status and provider specialty in infectious diseases were independent predictors of a provider's failure to recognize current smoking. Comorbid illnesses, cough/dyspnea, degree of immune competence and HIV viral suppression did not impact recognition of current smoking. Only 39% of HIV providers reported confidence in their ability to influence smoking cessation compared to 62% of non-HIV providers (p = .049).Conclusions: Interventions to increase HIV provider awareness of current smoking and skills to influence smoking cessation are needed. Efforts should also target patient populations with smoking-related comorbid diseases who would especially benefit from smoking cessation.


Related Articles

  • News from ISPOR.  // PharmacoEconomics & Outcomes News;6/30/2007, Issue 531, p6 

    The article focuses on various studies presented at the 12th International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in Arlington, Virginia in May 2007. Swedish researchers reported that varenicline is more cost effective than bupropion for smoking...

  • Physicians are a key to encouraging cessation of smoking among people living with HIV/AIDS: a cross-sectional study in the Kathmandu Valley, Nepal.  // BMC Public Health;2011, Vol. 11 Issue 1, p677 

    The article offers information on a study conducted by the authors on role of physicians to encourage smoking cessation in HIV/AIDS patients in Kathmandu Valley, Nepal. It states that a cross-sectional survey was conducted on patients which was analyzed using multiple logistic regression for...

  • Nicotine, CO and HCN: the detrimental effects of smoking on wound healing. Whiteford, Lesley // British Journal of Community Nursing;Dec2003, Vol. 8 Issue 12, pS22 

    Examines the effect of smoking on healing of acute wounds. Toxic components of cigarette smoke; Role of clinical practitioners in delivering evidence-based care; Smoking cessation programs for patients with wounds.

  • Changes in First-Line cART Regimens and Short-Term Clinical Outcome between 1996 and 2010 in The Netherlands. Smit, Mikaela; Smit, Colette; Geerlings, Suzanne; Gras, Luuk; Brinkman, Kees; Hallett, Timothy B.; de Wolf, Frank // PLoS ONE;Sep2013, Vol. 8 Issue 9, p1 

    Objectives: Document progress in HIV-treatment in the Netherlands since 1996 by reviewing changing patterns of cART use and relating those to trends in patients' short-term clinical outcomes between 1996 and 2010. Design and Methods: 1996–2010 data from 10,278 patients in the Dutch ATHENA...

  • Effects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected persons. Turner, Barbara J.; Fleishman, John A.; Wenger, Neil; London, Andrew S.; Burnam, M. Audrey; Shapiro, Martin F.; Bing, Eric G.; Stein, Michael D.; Longshore, Douglas; Bozzette, Samuel A.; Turner, B J; Fleishman, J A; Wenger, N; London, A S; Burnam, M A; Shapiro, M F; Bing, E G; Stein, M D; Longshore, D; Bozzette, S A // JGIM: Journal of General Internal Medicine;Sep2001, Vol. 16 Issue 9, p625 

    Objective: To distinguish the effects of drug abuse, mental disorders, and problem drinking on antiretroviral therapy (ART) and highly active ART (HAART) use.Design: Prospective population-based probability sample of 2,267 (representing 213,308) HIV-infected persons in...

  • The risk of HIV transmission at each step of the HIV care continuum among people who inject drugs: a modeling study. Escudero, Daniel J.; Lurie, Mark N.; Mayer, Kenneth H.; King, Maximilian; Galea, Sandro; Friedman, Samuel R.; Marshall, Brandon D. L. // BMC Public Health;7/25/2017, Vol. 18, p1 

    Background: People who inject drugs (PWID) are at continued risk for HIV in the U.S., and experience disparities across the HIV care continuum compared to other high-risk groups. Estimates of the risk of HIV transmission at each stage of the care continuum may assist in identifying...

  • Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. Dunn, David // BMJ: British Medical Journal (International Edition);12/10/2005, Vol. 331 Issue 7529, p1368 

    Objective To examine whether the level of primary resistance to HIV drugs is increasing in the United Kingdom. Design Multicentre observational study. Setting All virology laboratories in the United Kingdom carrying out tests for HIV resistance as part of routine clinical care. Participants 2357...

  • Risk Factors for and Outcome of Hyperlactatemia in HIV-Infected Persons: Is There a Need for Routine Lactate Monitoring? Imhof, Alexander; Ledergerber, Bruno; Günthard, Huldrych F.; Haupts, Stefan; Weber, Rainer // Clinical Infectious Diseases;9/1/2005, Vol. 41 Issue 5, p721 

    Background. Lactic acidosis is a rare but life-threatening complication of combination antiretroviral therapy (CART). Asymptomatic or mildly symptomatic episodes of hyperlactatemia are more frequent, but their clinical relevance is unknown. Methods. The incidences of, risk factors for, and...

  • Antiretroviral Therapy: Optimal Sequencing of Therapy to Avoid Resistance. Martinez-Cajas, Jorge L.; Wainberg, Mark A. // Drugs;2008, Vol. 68 Issue 1, p43 

    In the second decade of highly active antiretroviral therapy, drug regimens offer more potent, less toxic and more durable choices. However, strategies addressing convenient sequential use of active antiretroviral combinations are rarely presented in the literature. Studies have seldom directly...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics